Complement inhibitors and B-cell modifying agents for IgA nephropathy- a KDIGO commentary - PubMed
3 hours ago
- #IgA nephropathy
- #KDIGO guidelines
- #complement inhibitors
- The KDIGO updated its Clinical Practice Guideline for Glomerular Diseases in 2021 after slow progress, reflecting developments over a decade.
- Since 2021, novel therapies for IgA nephropathy (IgAN) have been successfully tested and approved, leading to another guideline update in 2025.
- After the 2025 update, three additional IgAN treatments received accelerated FDA approval, with two having different mechanisms of action than previously approved drugs.
- Given these new therapies, the KDIGO IgAN Work Group issued a commentary to outline their potential role in treatment strategies, pending further evidence.